Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A biomarker composition for non-small cell lung cancer, and screening and applications of the biomarker composition

A non-small cell lung cancer and biomarker technology, applied in the field of molecular medical diagnosis, can solve the problems of high tumor mortality, missing the best treatment time, lack of early diagnosis technology, etc., to achieve high prediction accuracy, early detection opportunity, Improve the effect of treatment

Active Publication Date: 2017-12-15
SHENZHEN UNIV
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, what is shocking is that due to the lack of effective early diagnosis techniques, nearly 80% of cancer patients are already in the middle and advanced stages when they are discovered, and the best treatment time is missed, so the tumor mortality rate is generally high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A biomarker composition for non-small cell lung cancer, and screening and applications of the biomarker composition
  • A biomarker composition for non-small cell lung cancer, and screening and applications of the biomarker composition
  • A biomarker composition for non-small cell lung cancer, and screening and applications of the biomarker composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1. Preliminary screening of differentially expressed miRNAs in non-small cell lung cancer

[0047] In this embodiment, the following steps are included:

[0048] (1) The goal of the present invention is to systematically study the relationship between circulating miRNAs and non-small cell lung cancer, in order to find a group of miRNAs that can be used as biomarkers for early diagnosis of non-small cell lung cancer. Firstly, the range of candidate research miRNAs was determined by literature search, and the search keywords were "microRNA / miRNA" and "cancer". A total of 486 miRNAs were identified as candidate research targets (Table 1).

[0049] (2) Preparation of mixed samples. All samples (from Shenzhen People's Hospital) were divided into three groups, including 266 healthy people's plasma, 130 non-small cell lung cancer stage I patients' plasma and 158 II-IV stage patients' plasma, which were mixed evenly.

[0050] (3) extract plasma total RNA, use S / P miR...

Embodiment 2

[0066] Example 2. Re-screening differentially expressed miRNAs in non-small cell lung cancer

[0067] In the second round of screening, the specific experimental operations were the same as in Example 1. 544 plasma samples from Shenzhen People's Hospital were divided into five groups: NC (N=266), ADC Stage I (N=96), ADC Stage II-IV (N=113), SCCStage I (N=34 ) and SCC Stages II-IV (N=45). The expression levels of the 125 miRNAs screened out in Example 1 were detected in five groups of mixed samples respectively. The selection criteria for this round of screening are: Stage I vs. NC: fold-change>2, or Stage II-IV vs. NC: fold-change>2. There were 30 miRNAs meeting the criteria in adenocarcinoma and 38 in squamous cell carcinoma ( Figure 4 ).

Embodiment 3

[0068] Example 3, adenocarcinoma / squamous cell carcinoma miRNA biomarker single verification pilot experiment

[0069] The miRNAs screened in Example 2 were firstly verified with a small number of random samples (collected in Shenzhen People's Hospital). The number of selected samples is: healthy group (NC) (N=20), adenocarcinoma stage I (N=20), adenocarcinoma stage II-IV (N=20), squamous cell carcinoma stage I (N=10) and Squamous cell carcinoma stage II-IV (N=10). The selection criteria for this round of screening are: Phase I vs. healthy group: fold-change>2, or Phase II-IV vs. healthy group: fold-change>2. There were 11 miRNAs meeting the criteria in adenocarcinoma and 10 in squamous cell carcinoma ( Figure 5 ). Among them, hsa-miR-32-5p, has-miR-183-5p, hsa-miR-144-5p, has-miR-144-3p and hsa-miR-574-3p are Ct in some adenocarcinoma and squamous cell carcinoma samples Values ​​greater than 35 are discarded. Therefore, in this example, 7 miRNAs (adenocarcinoma) and 9 m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of molecular medicine diagnosis, and particularly relates to a biomarker composition for non-small cell lung cancer, and screening and applications of the biomarker composition. The biomarker includes a lung adenocarcinoma biomarker and / or a squamous-cell carcinoma biomarker. The lung adenocarcinoma biomarker includes at least one of hsa-miR-26a-5p, hsa-miR-126-5p, hsa-miR-139-5p, hsa-miR-152-3p, hsa-miR-451a, hsa-miR-200c-3p and hsa-miR-3135b. The squamous-cell carcinoma biomarker includes at least one of hsa-miR-26a-5p, hsa-miR-126-5p, hsa-miR-139-5p, hsa-miR-151a-3p, hsa-miR-151a-5p, hsa-miR-151b, hsa-miR-152-3p, hsa-miR-550a-3p and hsa-miR-3135b. The invention also provides a biomarker screening method and applications of the biomarkers in early-stage non-small cell lung cancer diagnosis. Early-stage diagnosis and prediction of the non-small cell lung cancer are achieved, and are made rapider and more accurate. The non-small cell lung cancer can be found ahead of time, thus facilitating in-time and early treatment and increasing the survival rate.

Description

technical field [0001] The invention relates to the field of molecular medical diagnosis, in particular to a combination of biomarkers for non-small cell lung cancer, screening and application of the combination of biomarkers. Background technique [0002] According to the report of the World Health Organization, there are nearly 20 million new malignant tumor patients in the world every year, and about 11 million people die of malignant tumors. In my country, the incidence and death of malignant tumors are more severe. According to the "2013 China Tumor Registration Annual Report", there are about 3.5 million new cancer cases in my country every year, and an average of 6 people are diagnosed with cancer every minute; the cancer mortality rate is 13. %, that is, 1 death in every 7 to 8 people, with an annual death toll of 2.7 million. Among many malignant tumors, lung cancer has become the number one killer of human health. In terms of tumor treatment, various treatment tec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68C12N15/113
CPCC12Q1/6886C12Q2600/118C12Q2600/158C12Q2600/178
Inventor 苟德明牛燕琴吴伊可
Owner SHENZHEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com